Table 1 Summary of clinical and cytogenetic characteristics for the patient cohort.
From: “Direct to Drug” screening as a precision medicine tool in multiple myeloma
Clinical/cytogenetic category | Total number of evaluable samples | Classes | Number of samples per class (%) |
|---|---|---|---|
Diagnosis | 113 | Multiple myeloma (MM) | 99 (87.6%) |
Smoldering MM (SMM) | 14 (12.4%) | ||
Disease status | 113 | Untreated | 49 (43.4%) |
Early relapse | 16 (14.1%) | ||
Later relapse | 48 (42.5%) | ||
Risk group (mSMART 3.0) | 96 (MM) | Standard-risk | 36 (37.5%) |
High-risk (HR) | 60 (62.5%) | ||
60 (HR MM) | Double hit HR myeloma | 17 (28.3%) | |
Triple hit HR myeloma | 5 (8.3%) | ||
Cytogenetics—karyotype | 104 | Diploid | 38 (36.5%) |
Hyperdiploid | 61 (58.7%) | ||
Hypodiploid | 5 (4.8%) | ||
Cytogenetics—aberrations | 110 | t(11;14)/t(6;14) | 30 (27.3%) |
110 | Trisomies | 57 (51.8%) | |
110 | t(4;14) | 11 (10.0%) | |
110 | Del 17p | 10 (9.1%) | |
110 | Gain(1q) | 17 (15.5%) | |
110 | Del 13q | 38 (34.5%) | |
110 | Monosomy 13 | 47 (42.7%) | |
110 | MYC aberration | 17 (15.5%) |
